Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G17DT with Cisplatin and 5-FU in Gastric Cancer
NCT00042510Phase 2Completed
- Sponsor
- Cancer Advances, Inc.
- Start
- Aug 2000
- Primary completion
- Feb 2003
01
Overview
Phase 2, open-label trial of G17DT immunogen in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Cancer Advances, Inc. Primary endpoint: Objective Response Rate at 29 weeks. Started Aug 2000; status: completed.
02
Drugs
G17DT immunogen
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00042510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042510.